Article content SHANGHAI, April 20, 2026 (GLOBE NEWSWIRE) - Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that early clinical results...
SHANGHAI, April 20, 2026 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading GlobeNewswire Junshi Biosciences Presents Results from JS207 (PD-1/VEGF BsAb) Phase 2 Combo Studies and JS212 (EGFR/HER3 ADC) FIH Phase 1/2...
Article content JS207’s design is based on the high-affinity, clinically proven and differentiated anti-PD-1 drug, toripalimab as the backbone. The anti-PD-1 moiety of JS207 adopts a Fab structure to maintain binding affinity to PD-1, thereby attaining better enrichment in the...
#CT159: Preliminary results from a phase 2 study evaluating JS207 in combination with JS007 as first-line treatment for advanced hepatocellular carcinoma (HCC) The Phase 2 study (NCT06954467) aiming to evaluate the safety and efficacy of JS207 in combination with JS007...
This is a paid press release. Contact the press release distributor directly with any inquiries. CStone Presented Preclinical Data for Three Novel or Differentiated ADCs at AACR 2026, Including CS5007 (EGFR/HER3) PR Newswire Sun, April 19, 2026 at 7:15 PM...
SUZHOU, China, April 19, 2026 /PRNewswire/ -- CStone Pharmaceuticals ("CStone," HKEX: 2616), an innovation-driven biopharmaceutical company focused on the research and development of therapies for oncology, immunology, inflammation, and other key disease areas, today announced that the Company presented the...
The latest announcement is out from CStone Pharmaceuticals ( ($HK:2616) ). CStone Pharmaceuticals has presented new preclinical data on three proprietary antibody-d Claim 30% Off TipRanksUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock...
p95HER2 is commonly expressed in human epidermal growth factor receptor 2 (HER2)-positive breast cancer (BC) and is generated primarily from shedding of the extracellular domain of HER2. p95HER2 is oncogenic, driving aggressive tumor growth, and conferring drug resistance. Targeting p95HER2...
